Combination of emicizumab with simoctocog alfa for prophylaxis in previously untreated/minimally treated hemophilia A patients, and for managing inhibitor patients

Robert Sidonio¹, Shannon Meeks¹, Amy Shapiro², Marilyn Manco-Johnson³ and Michael Callaghan⁴

¹Emory University, Atlanta, GA USA and Children’s Healthcare of Atlanta, Atlanta, GA, USA; ²Indiana Hemophilia & Thrombosis Center, Indianapolis, IN, USA; ³Hemophilia and Thrombosis Center, University of Colorado, Denver, CO, USA; ⁴Children’s Hospital of Michigan, Detroit, MI, USA